Présentations UMR_S 1176 (ou impliquant des membres de l’UMRS1176) + présentations par un des membres du CRMW au congrès de l’ISTH à Toronto

Communications orales :

Peter Lenting: Factor VIII and VWF, rekindling a longstanding relationship

Session SSC Von Willebrand factor

Samedi 20 Juin 14H30. Room 718

 

Marijke Bryckaert: Abstract OR003: A GAIN-OF-FUNCTION MUTATION IN FILAMIN-A POTENTIATES PLATELET INTEGRIN ΑLPHA-IIB/ΒETA-3 ACTIVATION

Lundi 22 Juin 8H30. Room 718

 

Sophie Susen: Abstract OR024 TYPE 2N VON WILLEBRAND DISEASE: ONE VARIANT BUT MORE THAN ONE DISEASE (8:45)

Session VWD – classification, subtypes – I

Lundi 22 Juin 8H45, Room 716

 

Jenny Goudemand: Abstract OR025 HETEROGENEITY OF VON WILLEBRAND DISEASE TYPE 3 IN A FRENCH COHORT OF 75 PATIENTS (9 :00)

Session VWD – classification, subtypes – I

Lundi 22 Juin 9H00, Room 716

 

Jenny Goudemand: Abstract OR143: PLASMA-DERIVED FACTOR VIII PRODUCTS AND INHIBITOR DEVELOPMENT IN PREVIOUSLY UNTREATED BOYS WITH SEVERE HEMOPHILIA A : REPORT OF THE FRANCECOAG NETWORK

Session hemophilia inhibitors

Mardi 23 Juin 8h30, Room 801

 

Vincent Muczynski: Abstract OR246: MACROPHAGE-SPECIFIC RECEPTOR SR-AI PLAYS A CRUCIAL PROTECTIVE ROLE IN THE REGULATION OF COAGULATION FACTOR X PLASMA LEVELS.

Mardi 23 Juin 14H00. Room 709

 

Alexandre Kauskot: Abstract OR234: TYPE 2B VON WILLEBRAND DISEASE (VWD) IS CHARACTERIZED BY A CYTOSKELETAL DESORGANIZATION IN MEGAKARYOCYTES LEADING TO MACROTHROMBOCYTOPENIA.

Mardi 23 Juin 14H45. Room 717.

 

Antoine Rauch: Abstract OR219: EARLY VON WILLEBRAND FACTOR DEGRADATION UPON ACUTE EXPOSURE TO HIGH SHEAR STRESS UNDER CONTINUOUS-FLOW CIRCULATORY ASSIST DEVICES

Session Acquired disorders; Clinical II

Mardi 23 Juin, 14H45, Room 716

 

Frédéric Adam: Abstract OR205: CHARACTERIZATION OF A NEW GENETICALLY-ENGINEERED VON WILLEBRAND DISEASE TYPE 2B MOUSE MODEL.

Mardi 23 Juin 15H00. Room 701

 

Amine Bazaa: Abstract AS062: VON WILLEBRAND FACTOR IS INDISPENSABLE FOR VENOUS HEMOSTASIS IN A NOVEL MURINE BLEEDING MODEL

Mardi 23 Juin 17H15. Room 801

 

Caterina Casari: Abstract OR333: NEW IN VITRO AND IN VIVO STRATEGIES TO MODULATE VON WILLEBRAND FACTOR GENE MUTATIONS WITH DOMINANT-NEGATIVE EFFECT

Mercredi 24 Juin 14H30. Room 801

 

Antoine Rauch: Abstract AS134: ELISA-BASED ASSESSMENT OF EXCESSIVE VON WILLEBRAND FACTOR PROTEOLYSIS

Abstract Symposium: Assay challenges

Mercredi 24 Juin, 16H55, Room 709

 

Posters :

E Gouider: Abstract PO650-MON: EFFICACY AND SAFETY OF von WILLEBRAND FACTOR CONCENTRATE WITH A LOW FVIII CONTENT IN SEVERE VWD CHILDREN LESS THAN 6 YEARS OF AGE

Lundi 22 Juin 18H00-19H30, Section Von Willebrand disease I

 

François Saller: Abstract PO339-TUE: ANTITHROMBIN BINDS TO AND ENHANCES THE BARRIER FUNCTION OF HUVECS INDEPENDENTLY OF CELL-SURFACE HEPARAN SULFATE PROTEOGLYCANS

Mardi 23 Juin 18H00-19H30. Section Natural Anticoagulants

 

Judicaël Fazavana: Abstract PO553-TUE: THE LRP1 RECEPTOR PROMOTES THE IN VIVO CLEARANCE OF ACTIVATED FACTOR VII (FVIIA) IN COMPLEX WITH ANTITHROMBIN

Mardi 23 Juin 18H00-19H30. Section Tissue Factor and factor VII-II

 

Gabriel Aymé: Abstract PO658-TUE: CROSS-SPECIES INHIBITION OF HUMAN AND MURINE VON WILLEBRAND FACTOR BY A SINGLE DOMAIN VHH-ANTIBODY

Mardi 23 Juin 18H00-19H30. Section Von Willebrand factor II

 

Paulette Legendre: Abstract PO664-TUE: FUNCTIONAL STUDY OF TWO NEW MUTATIONS IN THE C4 DOMAIN OF VON WILLEBRAND FACTOR

Mardi 23 Juin 18H00-19H30. Section Von Willebrand factor II

 

Antoine Rauch: Abstract PO662-TUE: VON WILLEBRAND FACTOR TO MONITOR PERCUTANEOUS AORTIC VALVE INTERVENTIONS

Mardi 23 Juin 18H00-19H30. Section Von Willebrand factor II

 

Mathilde Giraud: Abstract PO645-TUE: WILLEBRAND DISEASE MOLECULE DIAGNOSIS BY HIGH THROUGHPUT SEQUENCING: WHAT’S ABOUT THE HIGLY HOMOLOGOUS PSEUDOGENE

Mardi 23 Juin 18H-19H30, Section von Willebrand disease II

 

Annie Borel-Derlon: Abstract PO639-TUE: HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND HEALTH-ECONOMIC ASSESSMENT IN PATIENTS WITH von WILLEBRAND DISEASE IN FRANCE: THE WISH-QOL STUDY;

Mardi 23 Juin 18H-19H30, Section von Willebrand disease II

 

Amine Bazaa: Abstract PO206-WED: DISCORDANT IN VITRO AND IN VIVO ACTIVITY OF FACTOR VIII MUTANTS

Mercredi 24 Juin 17H30-18H15. Section Coagulation factor VIII and IX – III

 

Ziane Elaib: Abstract PO444-WED: SPECIFIC REGULATION OF MOUSE PLATELET ADP SECRETION BY SARCO-ENDOPLASMIC RETICULUM CALCIUM ATPASE TYPE 3

Mercredi 24 Juin 17H30-18H15. Section Platelet activation/adhesion/aggregation III